

# Project Apollo Delphi



- Biologics company conducting international site search for the location of specialized therapeutics manufacturing facility to serve US and Canadian markets
- BVEDC and community partners have been engaged with the company since May 2018 to explore Brazos Valley
- Competitive site location process; Brazos Valley one of three locations under consideration
- Strong fit with community assets and talent pipeline

zoom

# Benefits to Our Community



- Creation of 300+ new jobs; average wage above the county average
- Expansion and diversification of the local tax base
- Additional life science career opportunities within the Brazos Valley to retain young talent
- Further reinforce the Brazos Valley's biotechnology cluster
- Opportunities for collaboration with other local life science companies in the Brazos Valley
- Strategic asset for the State of Texas

zoom

Julea Johnson

# Evolve Biologics® Chapter 313 Application

August 17, 2020

# Introduction to the Evolve Biologics Executive Team

Extensive commercial market and launch experience in pharma, plasma manufacturing and bleeding disorders



## DAVID HOLLIDAY – Chief Commercial Officer

- With over 30 years of pharmaceutical and biologics experience, David has held progressively senior commercial roles in both private and public companies
- He has successfully launched and commercialized a number of key >\$1 billion biologics in the United Kingdom, United States, and other global markets. Prior experience includes:
  - VP Commercial Operations for Octapharma USA
  - Global Vice President of Marketing Operations and Hemophilia for Baxter (now Shire)
  - Led Baxter's Bioscience business in the UK following a 17-year career with Novartis
- DMS from Kingston University in London



## MARK KRAUSE – Head of Plasma Proteins

- Mark served as Head of Plasma Proteins at Therapure Biopharma Inc. from 2011 until the formation of Evolve Biologics
- He previously held progressively senior positions within the finance operations at Valeant (formerly Biovail)
  - As Director, Financial Analysis and Planning, he worked closely with business development, R&D, and manufacturing, particularly during licensing transactions
- BSc in biology from the University of British Columbia and an MBA from Richard Ivey School of Business
- Certified Professional Accountant



# Evolve Biologics Company History


Wholly owned subsidiary of Therapure Biopharma, a leading Contract Development & Manufacturing Organization (CDMO)

## Business Overview


- Focused on development, manufacturing and commercialization of **plasma-derived therapeutics**
- Owns all global rights and IP for the use of PlasmaCap EBA® in the field of human plasma
  - Propriety technology which brings a simple, modern and innovative approach to the efficient extraction of proteins from human plasma
- Headquartered in Toronto, Canada with ~30 employees
- Wholly owned subsidiary of Therapure Biopharma, which is majority-owned by Catalyst Capital Group

## Today

- Poised to commence construction of commercial facility
- Filing FDA BLA for IVIG and Albumin




# Plasma Products : Evolve's De-risked Path to Market



# Committed Plasma Supply and Distribution

Evolve's strong in-place partnerships significantly reduce execution risk




# Sequenced, Scalable Growth Strategy

	Current Focus	Future Opportunities
Facility	<b>Build &gt;1M Liter US Facility for US Market</b> <ul style="list-style-type: none"> <li>Capital Required: ~\$140M USD</li> </ul>	<b>Build 2nd &gt;1M Liter US Facility for US Market (2026)</b> <ul style="list-style-type: none"> <li>Potential to build additional smaller modular facility and lab in Canada (and others internationally)</li> </ul>
Product Targets	<b>Existing High-Volume/Growth Products with Greatest Patient Need</b> <ul style="list-style-type: none"> <li>Focus on high value intravenous immunoglobulin (IVIg) and albumin (HSA)</li> <li>Clear and well-established supply chain</li> <li>Well-defined FDA regulatory guidance driven pathway for IVIg and albumin</li> </ul>	<b>New or Existing Plasma-Derived Therapeutics with Limited Availability</b> <ul style="list-style-type: none"> <li>Have identified other rare plasma-derived therapeutics such as Alpha-1 Antitrypsin (AAT) not efficiently extracted using cold ethanol fractionation</li> <li>Working with FDA to proactively explore practical and expedient regulatory pathways to approval</li> </ul>
Plasma Source	<b>Contracted with 3<sup>rd</sup> Party Plasma Suppliers</b>	<b>Augment Long-Term Contracts with Evolve Owned Collection Centers</b>
Distribution	<b>Partnerships with Strategic Market Players</b>	<b>Expand partnerships to facilitate volumes from 2<sup>nd</sup> Facility</b>
Markets	<b>North America</b> <ul style="list-style-type: none"> <li>US is single largest market for plasma-derived therapeutics and company's primary target</li> </ul>	<b>International</b> <ul style="list-style-type: none"> <li>Opportunistic commercial and licencing opportunities on a regional or country-by-country basis to support self-sufficiency</li> </ul>
TAM <sup>1</sup>	<b>\$12B</b>	<b>\$24B</b>

(1) Existing total addressable market (US\$). MRB: 2018 US and Global Reports.



# Commence Construction Early 2021 in the Bio-Corridor



# Evolve Biologics Chapter 313 Application Highlights

- Total estimated investment **\$140M**
- Commence **construction early 2021** in the **Bio-corridor**
- Two plasma protein products **launch by end of 2023**
- Value limitation starts in **tax year 2023**
- Estimated construction FTEs: **276 Peak FTEs** in 2021, Cumulative 711 over 3 years
- Planned Full Manufacturing Staff: **344 in 2026**

Economic Impacts	Construction		Value Limitation				Total
	2021	2022	2023	2024	2025	2026	
Investment (\$M)	60.5	51.5	28.5				<b>140.5</b>
Construction FTEs	222	276	213				<b>711</b>
Created Mfg Jobs	3	7	118	107	85	24	<b>344</b>